GWN Securities Inc. Invests $268,000 in Novo Nordisk A/S (NYSE:NVO)

GWN Securities Inc. purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 3,092 shares of the company’s stock, valued at approximately $268,000.

Other institutional investors have also modified their holdings of the company. Norman Fields Gottscho Capital Management LLC raised its holdings in shares of Novo Nordisk A/S by 45.3% during the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after acquiring an additional 19,870 shares during the period. Victory Capital Management Inc. raised its holdings in shares of Novo Nordisk A/S by 58.5% during the 4th quarter. Victory Capital Management Inc. now owns 62,897 shares of the company’s stock worth $5,410,000 after acquiring an additional 23,223 shares during the period. Bryn Mawr Capital Management LLC raised its holdings in shares of Novo Nordisk A/S by 358.8% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock worth $3,346,000 after acquiring an additional 30,420 shares during the period. Versant Capital Management Inc purchased a new position in shares of Novo Nordisk A/S during the 4th quarter worth $86,000. Finally, Talbot Financial LLC purchased a new position in shares of Novo Nordisk A/S during the 4th quarter worth $4,066,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Stifel Nicolaus downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. BMO Capital Markets cut their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an “equal weight” rating for the company. Finally, BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Three analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $80.26 on Tuesday. The company has a market cap of $360.15 billion, a P/E ratio of 24.39, a P/E/G ratio of 0.90 and a beta of 0.42. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The stock has a 50-day moving average of $83.85 and a two-hundred day moving average of $102.39. Novo Nordisk A/S has a 1-year low of $73.80 and a 1-year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a dividend of $0.7874 per share. The ex-dividend date of this dividend is Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s payout ratio is currently 47.72%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.